A randomized, double-blind, placebo-controlled study evaluating gevokizumab (monoclonal antibody targeting IL-1 beta) for the treatment of patients with relapsing GCA is ongoing and has recruited 13 patients to date (EudraCT number 2013–002778-38). The gene discussed is IL1B; the disease is temporal arteritis.